ArticleInvestigational new drugs2006
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.
Article in Investigational new drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 25 citations in OpenAlex.
- Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study.Interactive journal of medical research · 2021Article
- Animal Models of Colorectal Cancer: From Spontaneous to Genetically Engineered Models and Their Applications.Veterinary sciences · 2021Review
- Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.Archives of pharmacal research · 2021Review
- Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.Journal of biomolecular screening · 2016Article
- A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.Oncotarget · 2015Article
- Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies.Bioorganic & medicinal chemistry letters · 2011Article
- Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.Bioorganic & medicinal chemistry · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
DMU-135 (3,4-Methylenedioxy-3',4',5'-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit Apc(Min/+) mouse gastrointestinal adenoma formation. From 4-18 weeks of age animals received DMU-135 (0.2% w:w) in AIN93G diet. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 +/- 18.3% compared to controls (p < 0.001). Further characterisation of this promising chemopreventive agent is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.